<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:format>application/pdf</dc:format>
  <dc:source xml:lang="eng">Nature Communications</dc:source>
  <dc:title xml:lang="eng">Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction</dc:title>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:subject xml:lang="eng">Humans</dc:subject>
  <dc:subject xml:lang="eng">Female</dc:subject>
  <dc:subject xml:lang="eng">Ovarian Neoplasms Immunology</dc:subject>
  <dc:subject xml:lang="eng">Ovarian Neoplasms Drug Therapy</dc:subject>
  <dc:subject xml:lang="eng">Ovarian Neoplasms Pathology</dc:subject>
  <dc:subject xml:lang="eng">T-Lymphocytes, Regulatory Immunology</dc:subject>
  <dc:subject xml:lang="eng">T-Lymphocytes, Regulatory Drug Effects</dc:subject>
  <dc:subject xml:lang="eng">Macrophages Immunology</dc:subject>
  <dc:subject xml:lang="eng">Macrophages Drug Effects</dc:subject>
  <dc:subject xml:lang="eng">Immunoglobulin E Immunology</dc:subject>
  <dc:subject xml:lang="eng">Carcinoma, Ovarian Epithelial Immunology</dc:subject>
  <dc:subject xml:lang="eng">Carcinoma, Ovarian Epithelial Drug Therapy</dc:subject>
  <dc:subject xml:lang="eng">Receptors, IgE Metabolism</dc:subject>
  <dc:subject xml:lang="eng">Folate Receptor 1 Immunology</dc:subject>
  <dc:subject xml:lang="eng">Inflammation Immunology</dc:subject>
  <dc:subject xml:lang="eng">Middle Aged</dc:subject>
  <dc:subject xml:lang="eng">CD8-Positive T-Lymphocytes Immunology</dc:subject>
  <dc:description xml:lang="eng">Ovarian cancer is the most lethal gynaecological cancer and treatment options remain limited. In a recent first-in-class Phase I trial, the monoclonal IgE antibody MOv18, specific for the tumour-associated antigen Folate Receptor-?, was well-tolerated and preliminary anti-tumoural activity observed. Pre-clinical studies identified macrophages as mediators of tumour restriction and pro-inflammatory activation by IgE. However, the mechanisms of IgE-mediated modulation of macrophages and downstream tumour immunity in human cancer remain unclear. Here we study macrophages from patients with epithelial ovarian cancers naive to IgE therapy. High-dimensional flow cytometry and RNA-seq demonstrate immunosuppressive, Fc?R-expressing macrophage phenotypes. Ex vivo co-cultures and RNA-seq interaction analyses reveal immunosuppressive associations between patient-derived macrophages and regulatory T (Treg) cells. MOv18 IgE-engaged patient-derived macrophages undergo pro-inflammatory repolarisation ex vivo and display induction of a hyperinflammatory, T cell-stimulatory subset. IgE reverses macrophage-promoted Treg cell induction to increase CD8+ T cell expansion, a signature associated with improved patient prognosis. On-treatment tumours from the MOv18 IgE Phase I trial show evidence of this IgE-driven immune signature, with increased CD68+ and CD3+ cell infiltration. We demonstrate that IgE induces hyperinflammatory repolarised states of patient-derived macrophages to inhibit Treg cell immunosuppression. These processes may collectively promote immune activation in ovarian cancer patients receiving IgE therapy.</dc:description>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:identifier>doi:10.1038/s41467-025-57870-y</dc:identifier>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:date>2025</dc:date>
  <dc:publisher>Nature Portfolio</dc:publisher>
  <dc:type xml:lang="ita">Testo</dc:type>
  <dc:type xml:lang="ita">Articolo di rivista</dc:type>
  <dc:rights xml:lang="eng">© 2025. The Author(s)</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:language>eng</dc:language>
  <dc:creator>Gabriel Osborn</dc:creator>
  <dc:creator>Jacobo López-Abente</dc:creator>
  <dc:creator>Rebecca Adams</dc:creator>
  <dc:creator>Roman Laddach</dc:creator>
  <dc:creator>Melanie Grandits</dc:creator>
  <dc:creator>Heather J. Bax</dc:creator>
  <dc:creator>Jitesh Chauhan</dc:creator>
  <dc:creator>Giulia Pellizzari</dc:creator>
  <dc:creator>Mano Nakamura</dc:creator>
  <dc:creator>Chara Stavraka</dc:creator>
  <dc:creator>Alicia Chenoweth</dc:creator>
  <dc:creator>Lais C. G. F. Palhares</dc:creator>
  <dc:creator>Theodore Evan</dc:creator>
  <dc:creator>Jessica Hui Cheah Lim</dc:creator>
  <dc:creator>Amanda Gross</dc:creator>
  <dc:creator>Lenny Moise</dc:creator>
  <dc:creator>Shashi Jatiani</dc:creator>
  <dc:creator>Mariangela Figini</dc:creator>
  <dc:creator>Rodolfo Bianchini</dc:creator>
  <dc:creator>Erika Jensen-Jarolim</dc:creator>
  <dc:creator>Sharmistha Ghosh</dc:creator>
  <dc:creator>Ana Montes</dc:creator>
  <dc:creator>Ahmad Sayasneh</dc:creator>
  <dc:creator>Rebecca Kristeleit</dc:creator>
  <dc:creator>Sophia Tsoka</dc:creator>
  <dc:creator>James Spicer</dc:creator>
  <dc:creator>Debra H. Josephs</dc:creator>
  <dc:creator>Sophia N. Karagiannis</dc:creator>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:4122</dc:identifier>
</oai_dc:dc>